Zura Bio Ltd (ZURA) research

Zura Bio Ltd
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$4.50
As of

Zura Bio Ltd (ZURA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-17.

As of . Source: SEC EDGAR filings for ZURA. Method and limitations.

SHARE THIS CARD

Share the ZURA intelligence card

A branded snapshot of ZURA: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ZURA intelligence card preview
Post to X
LIVE TERMINAL

See ZURA live in the terminal

Track ZURA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ZURA terminal, free

Active signals for ZURA

FREE, NO ACCOUNT

Every signal on ZURA, as it fires

You are seeing 5 of 12 signals recorded on ZURA since 2026-05-31.

The five above landed across 2 days. The other 7 were recorded on 2 other days. 8 of the 12 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ZURA (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP G9TY5A101 · 2026Q2$2.1M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP G9TY5A101 · 2026Q2$1.9M0.00%,
CITADEL ADVISORS LLCCUSIP G9TY5A101 · 2026Q2$1.8M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP G9TY5A101 · 2026Q2$812K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ZURA

ZURA against its peers

ZURA's return on equity of -67.6% ranks in the 66th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricZURAPeer medianPercentilen
Revenue FYn/a25.1Mn/a14
Operating marginn/a-296.2%n/a12
Net marginn/a-320.7%n/a12
Return on equity-67.6%-80.5%6621

Peers (24): EDIT, IRD, CABA, ARTV, ARCT, CCCC, TTRX, RLMD, PRTA, SPRY, INDP, GALT, LRMR, PROK, PRLD, BNTC, FENC, BBOT, AGEN, MYGN, RCKT, RZLT, DMAC, ENTX. Left out: PRTC (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ZURA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ZURA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ZURAand get the insider, 13F, options, and confluence read in one view.

Open the live ZURA terminal, free